tbuckley/cabot-search huggingface dataset:
Uptake, Transport, and Toxicity of Pristine and Weathered Micro- and Nanoplastics in Human Placenta Cells
Authors: Hanna M. Dusza, Eugene A. Katrukha, Sandra M. Nijmeijer, Anna Akhmanova, A. Dick Vethaak, Douglas I. Walker, Juliette Legler
Journal: Environmental Health Perspectives (2022)

The first evidence of micro- and nanoplastic (MNP) exposure in the human placenta is emerging. However, the toxicokinetics and toxicity of MNPs in the placenta, specifically environmentally relevant particles, remain unclear.We examined the transport, uptake, and toxicity of pristine and experimentally weathered MNPs in nonsyncytialized and syncytialized BeWo b30 choriocarcinoma cells.We performed untargeted chemical characterization of pristine and weathered MNPs using liquid chromatography high-resolution mass spectrometry to evaluate compositional differences following particle weathering. We investigated cellular internalization of pristine and weathered polystyrene (PS; 0.05-10μm) and high-density polyethylene (HDPE; 0-80μm) particles using high-resolution confocal imaging and three-dimensional rendering. We investigated the influence of particle coating with human plasma on the cellular transport of PS particles using a transwell setup and examined the influence of acute MNP exposure on cell viability, damage to the plasma membrane, and expression of genes involved in steroidogenesis.Chemical characterization of MNPs showed a significantly higher number of unique features in pristine particles in comparison with weathered particles. Size-dependent placental uptake of pristine and weathered MNPs was observed in both placental cell types after 24 h exposure. Cellular transport was limited and size-dependent and was not influenced by particle coating with human plasma. None of the MNPs affected cell viability. Damage to the plasma membrane was observed only for 0.05μm PS particles in the nonsyncytialized cells at the highest concentration tested (100μg/mL). Modest down-regulation of hsd17b1 was observed in syncytialized cells exposed to pristine MNPs.Our results suggest that pristine and weathered MNPs are internalized and translocated in placental cells in vitro. Effects on gene expression observed upon pristine PS and HDPE particle exposure warrant further examination. More in-depth investigations are needed to better understand the potential health risks of MNP and chemicals associated with them under environmentally relevant exposure scenarios. https://doi.org/10.1289/EHP10873.
The impact of monkeypox outbreak on mental health and counteracting strategies: A call to action
Authors: Sirwan Khalid Ahmed, Salar Omar Abdulqadir, Safin Hassan Hussein, Rukhsar Muhammad Omar, Nabaz Ali Ahmed, Rawand Abdulrahman Essa, Kuldeep Dhama, Jose M. Lorenzo, Araz Qadir Abdulla
Journal: International Journal of Surgery (2022)
Deadly endemic zoonotic disease Ebola re-emerges in the democratic Republic of Congo amid the ongoing COVID-19: are we prepared from lessons learnt? – Correspondence
Authors: Ranjan K. Mohapatra, Snehasish Mishra, Venkataramana Kandi, Ashish K. Sarangi, Azaj Ansari, Gurudutta Pattnaik, Kuldeep Dhama
Journal: International Journal of Surgery (2022)
Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction
Authors: Vera Bittner
Journal: JAMA (1993)

<h3>Objective.</h3> —To study the potential usefulness of the 6-minute walk test, a self-paced submaximal exercise test, as a prognostic indicator in patients with left ventricular dysfunction. <h3>Design.</h3> —Data were collected during a prospective cohort study, the Studies of Left Ventricular Dysfunction (SOLVD) Registry Substudy. <h3>Setting.</h3> —Twenty tertiary care hospitals in the United States, Canada, and Belgium. <h3>Participants.</h3> —A stratified random sample of 898 patients from the SOLVD Registry who had either radiological evidence of congestive heart failure and/or an ejection fraction of 0.45 or less were enrolled in the substudy and underwent a detailed clinical evaluation including a 6-minute walk test. Patients were followed up for a mean of 242 days. <h3>Outcome Measures.</h3> —Mortality and hospitalization. <h3>Results.</h3> —During follow-up, 52 walk-test participants (6.2%) died and 252 (30.3%) were hospitalized. Hospitalization for congestive heart failure occurred in 78 participants (9.4%), and the combined endpoint of death or hospitalization for congestive heart failure occurred in 114 walk-test participants (13.7%). Compared with the highest performance level, patients in the lowest performance level had a significantly greater chance of dying (10.23% vs 2.99%;<i>P</i>=.01), of being hospitalized (40.91% vs 19.90%;<i>P</i>=.002), and of being hospitalized for heart failure (22.16% vs 1.99%;<i>P</i>&lt;.0001). In a logistic regression model, ejection fraction and distance walked were equally strong and independent predictors of mortality and heart failure hospitalization rates during follow-up. <h3>Conclusion.</h3> —The 6-minute walk test is a safe and simple clinical tool that strongly and independently predicts morbidity and mortality in patients with left ventricular dysfunction. (<i>JAMA</i>. 1993;270:1702-1707)
Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes
Authors: Lung‐Yi Mak, Rex Wan‐Hin Hui, Chi‐Ho Lee, XianHua Mao, Ka‐Shing Cheung, Danny Ka‐Ho Wong, David Tak‐Wai Lui, James Fung, Man‐Fung Yuen, Wai‐Kay Seto
Journal: Hepatology (2022)

Background and Aims: Type 2 diabetes (T2D) is common among patients with chronic hepatitis B infection (CHB) and has been associated with increased risk of carcinogenesis, including HCC. We investigated factors associated with HCC and fibrosis progression among patients with CHB with T2D (CHB+T2D). Approach and Results: Chinese patients with CHB were prospectively recruited for the incidence of HCC and fibrosis progression defined by transient elastography. Among patients with CHB+T2D, glycemic control was assessed by mean glycated hemoglobin (HbA1c) and HbA1c variability determined using HbA1c measurements in the 5 years preceding recruitment. A total of 2330 patients with CHB were recruited (mean age 54.6 ±11.8 years old, 55.5% male, 57.9% antiviral‐treated), with 671 (28.8%) having CHB+T2D (mean T2D duration 7.2 ± 4.6 years, mean HbA1c 7.2 ± 0.9%). T2D was independently associated with HCC (HR 2.080, 95% CI 1.343–3.222) and fibrosis progression (OR 4.305, 95% CI 3.416–5.424) in the overall cohort. In patients with CHB+T2D, factors reflecting glycemic burden (T2D duration [HR 1.107, 95% CI 1.023–1.198]), mean HbA1c (HR 1.851, 95% CI 1.026–3.339), time reaching target HbA1c (HbA1c‐TRT; HR 0.978, 95% CI 0.957–0.999), liver stiffness (HR 1.041–1.043), and smoking (HR 2.726–3.344) were independently associated with HCC (all p &lt; 0.05), but not HbA1c variability or controlled attenuation parameter. The same glycemic burden–related factors (T2D duration, mean HbA1c, and HbA1c‐TRT), in addition to baseline fasting glucose, baseline HbA1c, AST and antiviral therapy, were independently associated with fibrosis progression at 3 years. Conclusions: High glycemic burden was associated with HCC development and fibrosis progression among patients with CHB+T2D, highlighting the importance of glycemic control in reducing liver‐related complications.
2015 BioIron Meeting Abstracts
Authors: Francis Amagloh, Richard Mcbride, Tatiana Christides¹
Journal: American Journal of Hematology (2015)

Introduction: Iron deficiency anaemia (IDA) is a significant public health problem in Northern Ghana especially amongst women and children.Leafy green vegetables are major contributors to iron intake in this part of the world; poor iron bioavailability from these food sources may be part of the reason for the high prevalence of IDA.Evidence suggests that sweet potato and Moringa leaves might be better sources of bioavailable iron, compared with other leafy green vegetables, as both have high levels of iron, and also beta-carotene -a dietary factor that has been suggested to improve iron bioavailability.Aims/Hypothesis: Our research aims were to evaluate iron bioavailability of sweet potato and Moringa leaves in comparison with other leafy green vegetables commonly consumed in Ghana.We hypothesized that iron uptake from sweet potato and Moringa leaves would be higher compared with the other tested vegetables.Methods: We used the Caco-2 cell/in vitro digestion system; Caco-2 cell ferritin formation was used as a surrogate marker of iron bioavailability.In addition, we also measured levels of other nutrients and dietary factors known to affect iron bioavailability: beta-carotene, iron, calcium, zinc, ascorbate, phytates and polyphenols.Results: Iron bioavailability from all tested vegetables was poor despite relatively high absolute levels of iron in the leaf samples (14.5 -24.6 mg/100 grams dry weight); there was no statistically significant difference in iron uptake between any of the tested varieties or the control sample with no added iron.Levels of phytates and polyphenols, known inhibitors of iron uptake, were high and probably accounted for the low iron bioavailability of tested leaves.As expected, beta-carotene levels were highest in the sweet potato and Moringa leaves (ranging from 47-98 micrograms retinol activity equivalent)/gram freeze dried leaf)approximately 100% more compared with the other leafy green vegetables, with the exception of the purple leafed sweet potato variety tested that had approximately the same amount of beta-carotene as the commonly consumed vegetables. Conclusion:In our in vitro model neither sweet potato nor Moringa leaves demonstrated good iron bioavailability suggesting that increased consumption of these vegetables would not lead to improved iron status.However, both leaves were good sources of beta-carotene, and further testing in vivo to evaluate whether they could impact on vitamin A status may be warranted.
Use of Bacteriology in Anorectal Sepsis as an Indicator of Anal Fistula: Experience in a District General Hospital
Authors: G Nicholls, N D Heaton, A M Lewis
Journal: Journal of the Royal Society of Medicine (1990)

The bacteriology of anorectal sepsis in a district general hospital has been reviewed to see whether the information gained helped patient management. Forty-six patients with anorectal sepsis were reviewed, underlying fistulas were identified in nine patients (19.5%). Bacteroides species were not routinely subtyped in the department. It was found that isolation of unspecified Bacteroides species was not helpful in identifying those patients with underlying fistulas. Unless subtyping of Bacteroides species is specifically requested, pus from anorectal sepsis should not routinely be sent for bacteriology.
Use of Sedating Drugs and Neuromuscular Blocking Agents in Patients Requiring Mechanical Ventilation for Respiratory Failure
Authors: John H. Hansen-Flaschen
Journal: JAMA (1991)

<h3>Objective.</h3> —To assess current use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation at US hospitals that participate in the training of pulmonary fellows. <h3>Design.</h3> —Surveys were mailed in September 1990 to the head nurses of medical intensive care units at 265 US hospitals that were listed in an annual guide listing pulmonary fellowship training programs. In the survey, sedating drugs were defined as medications prescribed to treat anxiety, agitation, or sleeplessness. These included opiates, anesthetics, or neuroleptic agents when used for any of these purposes. <h3>Survey Respondents.</h3> —Surveys were received from nurses at 164 hospitals (62% response rate) representing 93 medical schools and 100 pulmonary fellowship training programs. Nearly half of the respondents worked at university hospitals. Most worked as head nurses in medical (70%) or medical-surgical (21%) intensive care units (ICUs). <h3>Results.</h3> —Sedating drugs were given to patients undergoing mechanical ventilation at virtually all the ICUs surveyed, and 36% used these drugs routinely (&gt;70% of patients). Opiates and benzodiazepines were employed most commonly; haloperidol lactate was widely used as well. Intermittent intravenous injection was the preferred method of administration; 62% of the ICUs also gave these drugs by continuous intravenous infusion. Neuromuscular blocking agents were also used at nearly all the ICUs surveyed; however, most gave these drugs to fewer than 20% of patients experiencing respiratory failure. Orders for the use of sedating drugs and neuromuscular blocking agents were written exclusively by house staff at 65% of the ICUs surveyed. <h3>Conclusions.</h3> —Sedating drugs and neuromuscular blocking agents are widely used for patients requiring mechanical ventilation in ICUs at US teaching hospitals. There is considerable variation in the choice, frequency, and method of administration. Given the expense (up to $1000 a day) and the potential hazards to patients of prolonged deep sedation and paralysis, more research is warranted to determine optimal use of these drugs during mechanical ventilation. (<i>JAMA</i>. 1991;266:2870-2875)
EP03.01-003 Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)
Authors: G. Werutsky, O. Arrieta, M. Zukin, C. Mathias, A.C.Z. Gelatti, D.L. Kaen, A.F. Cardona, E. Cronemberg, C. Campos, L.H. Araújo, H. de Andrade, S.L. Reichow, V.C. de Lima, P. Pacheco, J.C. Coelho, G. Borges, A. Silva, E. Mascarenhas, A. Quiroga, L. Fein, F.N.G. de Oliveira, J. Pastorello, C. Dutra, I. Morbeck, F.S.M. Cruz, T.F. Rebelatto, R. Gomes, C.H. Barrios
Journal: Journal of Thoracic Oncology (2022)
MA12.03 Mechanims of Immune Evasion in Patients With KRAS-Mutant Lung Adenocarcinoma: A Role of MAPK Pathway Activation
Authors: D. Naves, T.J. van Ee, F. van Maldegem, T.D. de Gruijl, Y. van Kooyk, T. Radonic
Journal: Journal of Thoracic Oncology (2022)
P1.14-01 Transcriptomic Analysis of Malignant Pleural Mesothelioma (MPM) Reveals Insights for Basic Research and Preclinical Testing
Authors: A. Laure, A. Rigutto, M.B. Kirschner, L. Opitz, I. Opitz, S. Hiltbrunner, A. Curioni-Fontecedro
Journal: Journal of Thoracic Oncology (2022)
MA14.08 Longitudinal Symptoms and Health Utility Scores (HUS) in Patients Receiving PD-1 Inhibitors for Metastatic NSCLC
Authors: C. Poletes, S.C. Cheng, L.J. Zhan, J. Lee, D. Patel, P.A. Bradbury, F.A. Shepherd, N.B. Leighl, A.G. Sacher, G. Liu, S.C. Lau
Journal: Journal of Thoracic Oncology (2022)
MA05.08 MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History
Authors: J. Marks, J. Yin, B. Halmos, L. Bazhenova, S.S. Ramalingam, M.E. Marmarelis, J. Xiu, P. Walker, M. Oberley, P.C. Ma, S.V. Liu
Journal: Journal of Thoracic Oncology (2022)
EP02.03-006 Oncological Outcome And Surgical Instruments in VATS Lobectomy For Early Stage Lung Cancer
Authors: F. Femia, F. Guerrera, E. Della Beffa, R.C. Cristofori, P.L. Filosso, E.C. Fontana, P.O. Lausi, P. Lyberis, M. Roffinella, E. Passone, M. Gallo, E. Ruffini
Journal: Journal of Thoracic Oncology (2022)
P2.14-04 Re-Definition of Lung Adenocarcinoma Transcriptional Subtypes Using Integrative Bioinformatics Approaches
Authors: S. Hijazo-Pechero, A. Alay, D. Cordero, R. Marín, A. Villanueva, R. Palmero, J. Brenes, N. Vilariño, M. Martinez-Iniesta, C. Muñoz-Pinedo, E. Nadal, X. Solé
Journal: Journal of Thoracic Oncology (2022)
MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
Authors: M.E. Marmarelis, S.-H. Lee, A.I. Spira, S.-H.I. Ou, S. Waqar, S. Li, M. Thayu, R.E. Knoblauch, J.M. Bauml, B.C. Cho
Journal: Journal of Thoracic Oncology (2022)
P1.07-02 Personal and Family HiStory of CANcer in Patients with Non-small Cell Lung Cancer: Preliminary Data of the SCAN Study
Authors: J.C. Laguna, L. Gonzalez-Aguado, E. Auclin, J. Torres-Jiménez, V. Albarrán-Artahona, B. Pastor, T. Gorría, L. Moreno, M. Potrony, R. Reyes, D. Martínez, O. Castillo, N. Viñolas, L. Gaba, B. Adamo, A. Arcocha, J.A. Puig-Butillé, A. Prat, C. Teixidó, N. Reguart, L. Mezquita
Journal: Journal of Thoracic Oncology (2022)
EP02.01-005 The Efficacy of Platinum-Based Chemotherapy as Adjuvant Therapy in EGFR Mutant Lung Adenocarcinoma
Authors: K. Onodera, K. Aokage, M. Wakabayashi, T. Ikeno, J. Suzuki, T. Miyoshi, K. Tane, J. Smajima, M. Tsuboi
Journal: Journal of Thoracic Oncology (2022)
EP07.01-011 Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma
Authors: L.A. Cabrera, A. Aviles-Salas, N. Hernandez-Pedro, M. Orozco-Morales, D. Motola-Kuba, W. Muñoz, M. Ramos-Ramirez, D. Heredia, L. Lara-Mejia, P.D. Soberanis-Piña, L. Corrales, C. Martin, A.F. Cardona, O. Arrieta
Journal: Journal of Thoracic Oncology (2022)
OA12.03 Phase 2 Study Analysis of Talazoparib (TALA) Plus Temozolomide (TMZ) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Authors: J. Goldman, A. Cummings, M. Mendenhall, M.A. Velez, S. Babu, T. Johnson, J. Alcantar, S. Dakhil, D. Kanamori, W. Lawler, S. Anand, J. Chauv, E. Garon, D. Slamon
Journal: Journal of Thoracic Oncology (2022)
EP02.01-011 Immune-related Histologic Phenotype in Pretreatment Tumor Biopsy Predicts Efficacy of Neoadjuvant Anti-PD-1 Treatment in Squamous Lung Cancer
Authors: P. Yuan, C.C. Guo, L. Li, Y. Ling, L. Guo, J. Ying
Journal: Journal of Thoracic Oncology (2022)
MA03.04 An Integrated Deep Learning Method to Predict Lung Cancer Recurrence Risk for Resected Stage IA NSCLC
Authors: P. Huang, P.B. Illei, W. Franklin, P.-H. Wu, P.M. Forde, S. Ashrafinia, C. Hu, X. Kong, H. Khan, H. Vadvala, I.-M. Shih, R. Battafarano, M.A. Jacobs, Y. Chen, F. Housseau, A. Rahmim, E.K. Fishman, D.S. Ettinger, K.J. Pienta, D. Wirtz, M.V. Brock, E. Gabrielson, S. Lam
Journal: Journal of Thoracic Oncology (2022)
EP16.01-005 Cilia-related mRNA Profile Predicts Clinical Response to PD-1 Blockade in Lung Adenocarcinoma
Authors: G. Gao, T. Jiang, F. Zhou, F. Wu, W. Li, A. Xiong, X. Chen, S. Ren, C. Su, T. Hu, Q. Li, C. Zhu, C. Zhou
Journal: Journal of Thoracic Oncology (2022)
OA10.03 A Randomized Trial of Telephone-Based Smoking Cessation Treatment in the Lung Cancer Screening Setting
Authors: R. Williams, P. Cao, T. Li, G. Luta, L. Smith, J. Mandelblatt, J. Jeon, A. Zhao, D. Levy, K. Davis, C. Stanton, R. Niaura, D. Abrams, T. Lobo, E. Anderson, R. Meza, J. Jayasekera, K.L. Taylor
Journal: Journal of Thoracic Oncology (2022)
P2.10-05 Circulating CD3+CD56+ Cells as a Biomarker for Immunotherapy in SCLC.
Authors: V. longo, A. negri, S. De Summa, P. Pizzutilo, A. Catino, M. Montrone, S. Montagna, F. Pesola, I. Marech, N. Varesano, G. Del Bene, A. Perrone, M. Gesualdo, P. Petrillo, A. Guarini, D. Galetta
Journal: Journal of Thoracic Oncology (2022)
P2.13-03 Plasma Profiling Unveils Transcriptional Signatures Associated with Resistance to Osimertinib in Non-Small Cell Lung Cancer
Authors: A. Alexeyenko, O.T. Brustugun, I.J. Zwicky Eide, R. Gencheva, Z. Kosibaty, Y. Lai, L. de Petris, G. Tsakonas, O. Grundberg, B. Franzen, K. Viktorsson, R. Lewensohn, P. Hydbring, S. Ekman
Journal: Journal of Thoracic Oncology (2022)
EP02.01-010 Preoperative PET-SUVmax and Volume Based PET Metrics of the Tumor Fail to Predict Nodal Upstaging in Early-Stage Lung Cancer
Authors: O. Okumus, K. Mardanzai, T. Ploenes, D. Theegarten, K. Darwiche, M. Schuler, F. Nensa, H. Hautzel, M. Stuschke, B. Hegedues, C. Aigner
Journal: Journal of Thoracic Oncology (2022)
P1.02-02 Current Status, Challenges and Perspectives of Lung Cancer Screening in Low- and Middle-Income Countries
Authors: M. Cavic, A. Kerpel-Fronius, L. Viola, L. Ventura, L. Jiang, R. Sales dos Santos, D. Yang, C. Koegelenberg, J. Zulueta, C. Henschke, E. Kazerooni, M. Tammemägi, J. Field, M. Wynes, H. Balata, D. Yankelevitz, G. Sozzi, S. Lam, R. Huber
Journal: Journal of Thoracic Oncology (2022)
P1.12-05 Prediction of Clinically Significant Pathological Upstaging in Resected Lung Cancer: Insight from COVID-19 Pandemic (1st wave)
Authors: Y.Z. Zhang, A.G. Nicholson, F. Ly, A. Rice, J.L. Robertus, E. Lim, S. Begum, S. Buderi, V. Anikin, J. Finch, N. Asadi, S. Popat, F. McDonald, P. De Sousa, P.L. Molyneaux, M.F. Moffatt, W.O. Cookson, S. Kemp, P.L. Shah, C.A. Ridge, S. Desai, S. Padley, A. Devaraj, S. Jordan, E. Beddow, C. Brambilla
Journal: Journal of Thoracic Oncology (2022)
EP02.01-014 Prognostic Classification of Early-Stage Lung Cancer Using Preoperative Prealbumin and D-dimer Levels
Authors: T. Yamamichi, J. Ichinose, S. Tamagawa, K. Omura, K. Hashimoto, Y. Matsuura, M. Nakao, S. Okumura, M. Mun
Journal: Journal of Thoracic Oncology (2022)
MA03.08 Survival Impact of Benchmarking Lung Cancer Surgeons’ Performance by Quality Metrics
Authors: M. Ray, M. Smeltzer, N. Faris, C. Fehnel, W. Akinbobola, A. Saulsberry, K. Dortch, A. Pacheco, P. Levi, T. Ng, E.T. Robbins, R. Osarogiagbon
Journal: Journal of Thoracic Oncology (2022)
EP05.02-019 Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
Authors: Y. Pilon, M. Rokah, R.F. Rayes, J. Cools-Lartigue, S. Najmeh, C. Sirois, D. Mulder, L. Ferri, B. Abdulkarim, N. Ezer, R. Fraser, S. Camilleri-Broët, P.-O. Fiset, A. Wong, S. Sud, A. Langleben, J. Agulnik, C. Pepe, B. Shieh, V. Hirsh, L. Ofiara, S. Owen, J.D. Spicer
Journal: Journal of Thoracic Oncology (2022)
EP16.01-014 Characterisation of Circulating Immune Cells in a Cohort of Non-small Cell Lung Cancer Patients Treated with Immunotherapy
Authors: M. Gascón- Ruiz, J. Pardo, M. Cruellas, P. Esteban, E.M. Galvez, R. Lastra, L. Martinez-Lostao, M. Ocariz, J.R. Paño, E. Quilez, A. Ramirez, A. Sesma, I. Torres-Ramón, A. Yubero, M. Zapata, D. Isla
Journal: Journal of Thoracic Oncology (2022)
MA02.03 The Evolution of Lung Neuroendocrine Tumors
Authors: N. Alcala, T. Dayton, A. Di Genova, A. Sexton-Oates, C. Voegele, F. Damiola, S. Tabone-Eglinger, L. Mangiante, E. Mathian, L.N.E.N. network, N. Girard, S. Lantuejoul, H. Clevers, L. Fernandez-Cuesta, M. Foll
Journal: Journal of Thoracic Oncology (2022)
EP08.02-107 Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer
Authors: M. Villanueva, K. Brice, K. Dumais, C.R. Carracedo Uribe, O. Nano, M. Rodriguez, E. Osmon, L. Raez
Journal: Journal of Thoracic Oncology (2022)
Association between a low response to rubella vaccination and reduced anti-severe acute respiratory syndrome coronavirus 2 immune response after vaccination with BNT162b2: a cross-sectional study
Authors: Kazuhiko Nakaharai, Yasushi Nakazawa, Yukie Mishima, Mari Saito, Yoichi Shinozaki, Masaki Yoshida
Journal: Clinical Microbiology and Infection (2022)
EP01.03-002 Implementation of the International Lung Screen Trial (ILST) in Catalonia: A Cost Analysis study
Authors: A. Rosell, S. Baeza, F. Lopez-SeguÍ, R. Mouriño, M. Saigí, M. Munné, J. Bechini, A. Gonzalez, E. Cervera, M. Compte, S. Garcia-Reina, A. NUÑEZ, J. ARA
Journal: Journal of Thoracic Oncology (2022)
EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy
Authors: M. Li, S. Zhao, J. Guo, T. Gauntner, J. Schafer, K. Chakravarthy, G. Lopez, A. Secor, P. Das, N. Surya, M. Husain, S. Patel, M. Grogan, D. Spakowicz, A. Miah, L. Wei, K. He, E. Bertino, A. Alahmadi, R. Memmott, J. Kaufman, C. Presley, P. Shields, D. Carbone, G. Otterson, D. Owen
Journal: Journal of Thoracic Oncology (2022)
P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial
Authors: L. Landi, M. Tiseo, L.C. Heukamp, R. Menon, F. de Marinis, G. Minuti, D.L. Cortinovis, A. Delmonte, D. Galetta, M. Bertrand, A. Zacher, C. Gridelli, F. Jacobs, R. Chiari, C. Verusio, D. Giannarelli, L. Crinò, F. Cappuzzo
Journal: Journal of Thoracic Oncology (2022)